SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51028Struggle for power is devastating population effected with ebola, and individualMiljenko Zuanic-8/14/2019
51027Recent weakness in the share price of Ionis Pharmaceuticals appears to be relateArt Bechhoefer-8/14/2019
51026Much needed in some places: reuters.comnigel bates-8/14/2019
51025Indeed, “Now we can say that 90 percent can come out of treatment cured, they wiMiljenko Zuanic-8/13/2019
51024Good news re Ebola: nytimes.comnigel bates-8/13/2019
51023"That would seem to open them up for all the other indications like Cancer Art Bechhoefer-8/12/2019
51022That would seem to open them up for all the other indications like Cancer anemiaJamesK-8/10/2019
51021I'm still scratching my head regarding comparing roxadust against a placebo A.J. Mullen-8/9/2019
51020Buying anything in this market is getting dangerous, owing mainly to concerted pArt Bechhoefer-8/9/2019
51019The call seemed clearer than the last one and pretty positive. Was that your inCpi3663-8/9/2019
51018FGEN pretty much came out and said not to worry about non-inferiority after theyBiomaven18/8/2019
51017Fibrogen's reported, 8k and call information, seekingalpha.comA.J. Mullen-8/8/2019
51016>>Should we trust Basf? Yes, but very few have ever even heard of them. Biomaven-8/3/2019
51015I agree that there is very low trust when come to bottle content, coming from AsMiljenko Zuanic-7/31/2019
51014Once there are 20 lookalikes, many from unknown sources, nobody will have the slBiomaven37/31/2019
51013The GHDX/EXAS story is getting more complicated. There are now 6 law firms inveA.J. Mullen-7/30/2019
51012Agreed, but even allowing for a 10% rise pre-announcement, an overall 15% premiuA.J. Mullen17/29/2019
51011Some info on vascepa, IF one want to dig in: pharmacompass.comMiljenko Zuanic-7/29/2019
51010The [GHDX] premium doesn't seem very enticing to me even if the current priDewDiligence_on_SI-7/29/2019
51009GHDX also announced their earnings today, "In the second quarter of 2019 weA.J. Mullen-7/29/2019
51008Exact Sciences signs deal to buy Genetic Health finance.yahoo.com. A law firm iA.J. Mullen-7/29/2019
51007< you can't trust the lookalikes once it goes OTC > What is on OmegasMiljenko Zuanic-7/29/2019
51006Exact Sciences said to be talking with Genomic Health about buying them, bloombeA.J. Mullen-7/28/2019
51005Thanks, Peter, and (for your cheerleading! ): lol) Julius. Did some digging intquidditch-7/28/2019
51004Michael Yee Ranked #1,030 out of 5,256 Analysts on TipRanks. Success 49% AveraJulius Wong-7/28/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News